LYS228 + Standard of care therapy
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intra-abdominal Infections
Conditions
Intra-abdominal Infections
Trial Timeline
May 15, 2018 → Sep 24, 2018
NCT ID
NCT03354754About LYS228 + Standard of care therapy
LYS228 + Standard of care therapy is a phase 2 stage product being developed by Novartis for Intra-abdominal Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT03354754. Target conditions include Intra-abdominal Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03377426 | Phase 2 | Withdrawn |
| NCT03354754 | Phase 2 | Terminated |
Competing Products
20 competing products in Intra-abdominal Infections